Welcome to Alitair Pharmaceuticals, Inc.

Alitair is a specialty pharmaceutical company with a focus on the respiratory space. Currently, we are developing two orphan drugs for bronchiectasis. We expect to begin phase II clinical trials for both compounds within the next 6 months.


We also have products under development for prescription and over-the-counter cough treatment.  Our lead cough candidate is a solid oral dosage form of benzonatate which is protected by a composition-of-matter patent.


Currently, Alitair has four issued patents and we expect to expand our patent portfolio in the near future.


This email address is being protected from spambots. You need JavaScript enabled to view it. for more information about our orphan drug candidates, our overdose reduction technology, and our cough licensing opportunities.